Clinical observation of intravenous alteplase thrombolytic therapy in patients with ischemic cerebrovascular disease
Objective To analyze the clinical efficacy of intravenous alteplase thrombolytic therapy in patients with ischemic cerebrovascular disease.Methods According to the established program of computer software,40 patients with ischemic cerebrovascular disease were selected,and they were divided into a control group and an observation group,with 20 cases in each group.The control group received conventional treatment,and the observation group received intravenous alteplase thrombolytic therapy.The clinical efficacy,neurological function,activities of daily living,occurrence of adverse events and satisfaction were compared between the two groups.Results After 2 h,24 h,14 d and 3 months of treatment,the neurological deficit scores in the observation group were(9.25±4.21),(7.14±3.02),(5.36±1.27)and(3.21±1.02)points,which were lower than(13.55±7.25),(11.36±4.25),(8.96±4.01)and(6.05±2.58)points in the control group,and the difference was statistically significant(P<0.05).The total effective rate of 95.00%in the observation group was significantly higher than 65.00%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in activities of daily living score between the two groups(P>0.05).After treatment,the activities of daily living score of(83.58±5.25)points in the observation group was higher than(71.58±5.36)points in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse events in the observation group was 5.00%,which lower than 30.00%in the control group,and the difference was statistically significant(P<0.05).The satisfaction of the observation group was 95.00%,which was higher than 65.00%of the control group,and the difference was statistically significant(P<0.05).Conclusion Intravenous alteplase thrombolytic therapy for patients with ischemic cerebrovascular disease can effectively alleviate the degree of neurological impairment in patients,better control the probability of adverse events in patients,and achieve an ideal prognosis and treatment effect closer to the ideal state,which is worthy of widespread clinical promotion.
AlteplaseIntravenous thrombolysisIschemic cerebrovascular diseaseQuality of lifeNeurological function
NETL
NSTL
万方数据
维普
